Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
CAR-T Trailblaze | Cabaletta Bio leads in developing CAR-T therapies for autoimmune diseases, targeting conditions like lupus and myositis with promising clinical results |
Market Disconnect | Explore the intriguing gap between positive clinical reception and market skepticism, presenting a unique investment opportunity in the biotech secto |
Strategic Positioning | Delve into Cabaletta's first-mover advantage in CD19 auto-CAR-T therapy and its potential to reshape treatment paradigms for autoimmune disorders |
Future Prospects | Analyst targets range from $6 to $35, reflecting diverse views on Cabaletta's potential to capitalize on its innovative therapies and market position |
Metrics to compare | CABA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCABAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −2.1x | −0.7x | |
PEG Ratio | 0.03 | 0.02 | 0.00 | |
Price/Book | 1.4x | 1.5x | 2.6x | |
Price / LTM Sales | - | 9.1x | 3.4x | |
Upside (Analyst Target) | - | 87.2% | 38.2% | |
Fair Value Upside | Unlock | 19.4% | 4.6% | Unlock |